Bio-Path Holdings Inc - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-24T13:10:51Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 24 noiembrie 2024 16:10
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Bio-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to [[PROTECT\|protect]] the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.		[[BIO\|Bio]]-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to [[PROTECT\|protect]] the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-09-29T16:25:49Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 29 septembrie 2024 19:25
Linia 1:		Linia 1:
	Pagina dedicata companiei Bio-Path Holdings Inc listata cu simbolul US.BPTH		Pagina dedicata companiei [[BIO-PATH HOLDINGS\|Bio-Path Holdings]] Inc listata cu simbolul US.BPTH

	==Descriere companie==		==Descriere companie==
	Bio-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.		Bio-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to [[PROTECT\|protect]] the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Bio-Path Holdings Inc listata cu simbolul US.BPTH ==Descriere companie== Bio-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (D...

2024-09-18T13:43:34Z

Pagină nouă: Pagina dedicata companiei Bio-Path Holdings Inc listata cu simbolul US.BPTH ==Descriere companie== Bio-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (D...

Pagină nouă

Pagina dedicata companiei Bio-Path Holdings Inc listata cu simbolul US.BPTH

==Descriere companie==
Bio-Path Holdings, Inc. (www.biopathholdings.com) is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.BPTH" />

==Ultimele stiri despre Bio-Path Holdings Inc (US.BPTH)==
<dynamicpagelist>
category=US.BPTH
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.BPTH]][[Categorie:Stiri despre companii]]